RPG Life Sciences eyes GLP-1 entry, US market via plant acquisitions
The company sharpens its domestic specialty formulations focus and looks to scale APIs through acquisitions, while planning partnership-led GLP-1 launches
Why you need a GLP-1 exit plan
I’ve seen clients start GLP-1 medications full of hope, and stop them feeling betrayed by their own biology. Some reached their limit with side effects: relentless nausea, fatigue, or the quiet loss of joy in eating. Others simply couldn’t afford to stay on. A few never saw the promised results at all. But for nearly […]
GLP-1 Drugs and AMD: What We’ve Learned So Far
(MedPage Today) — GLP-1 receptor agonists are being linked to a long list of benefits besides weight loss and diabetes, as evidence suggests they can lower the risk of conditions ranging from cancer and addiction to suicidal ideation, stroke…
Mechanisms of Glucagon‐Like Peptide 1 Receptor Agonist‐Induced Facial Lipodystrophy and a Path Toward Prevention
ABSTRACT Background The emergence of a distinct facial appearance characterized by pronounced hollowing of the cheeks, temples, chin, and periorbital region has become a noteworthy side effect of treatment with glucagon-like peptide 1 receptor agonists (GLP-1RAs). This phenomenon presents a growing concern in both dermatology and aesthetic medicine. The reduction of facial adipose tissue in […]
IJMS, Vol. 26, Pages 11548: From Phytochemistry to Metabolic Regulation: The Insulin-Promoting Effects of Loureirin B Analogous to an Agonist of GLP-1 Receptor
IJMS, Vol. 26, Pages 11548: From Phytochemistry to Metabolic Regulation: The Insulin-Promoting Effects of Loureirin B Analogous to an Agonist of GLP-1 Receptor International Journal of Molecular Sciences doi: 10.3390/ijms262311548 Authors: Haowen Fang Xiaodong Sun Yanting Ding Siyuan Gu Bing Niu Qin Chen This study aimed to develop a potent, safe, and cost-effective small-molecule hypoglycemic […]
Healthcare, Vol. 13, Pages 3102: Exploring Adults’ Experiences with Tirzepatide for Weight Loss: A Mixed-Methods Study
Healthcare, Vol. 13, Pages 3102: Exploring Adults’ Experiences with Tirzepatide for Weight Loss: A Mixed-Methods Study Healthcare doi: 10.3390/healthcare13233102 Authors: Shukri Adam Fatma M. Ibrahim Eman Abdelaziz Ahmed Dabou Sneha Pitre Rania Aiman Shimaa AbdelSamad Background: Obesity confers substantial cardiometabolic risk. Tirzepatide, a once-weekly dual GIP/GLP-1 receptor agonist, produces dose-dependent weight loss in trials, but […]
Nutrients, Vol. 17, Pages 3735: Beyond Weight Loss: GLP-1 Usage and Appetite Regulation in the Context of Eating Disorders and Psychosocial Processes
Nutrients, Vol. 17, Pages 3735: Beyond Weight Loss: GLP-1 Usage and Appetite Regulation in the Context of Eating Disorders and Psychosocial Processes Nutrients doi: 10.3390/nu17233735 Authors: Isabel Krug An Binh Dang Jade Portingale Yakun Li Ying Qing Won Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed treatment for higher weight and diabetes. Because they also […]
Beauty Is Changing Its Game Plan for the Ozempic Era
From surgery to supplements, GLP-1 medications are radically evolving the beauty space. We unpack the latest innovations.
Opinion: Public health should embrace GLP-1 drugs without abandoning obesity prevention
Following the White House’s recent announcement of price reductions and expanded coverage for GLP-1 medications like Wegovy and Zepbound, many patients searching for obesity treatments are about to gain access to highly effective options. The implications for U.S. public health are vast. Read the rest…
Get the Government Out of the GLP-1 Market
Its involvement often leads to distortions and perverse incentives. Dr. Gilberto de Lima Lopes Jr. is right that the market for medications is imperfect, but it is often government that is the culprit (“ The Free Market Alone Won’t Cut GLP-1 Prices,” Letters, Nov. 21). Oncology, his speciality, is the …